{"id":"pretomanid-pa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL227875","moleculeType":"Small molecule","molecularWeight":"359.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the synthesis of tetrahydrofolate, a necessary precursor for DNA synthesis and repair in the bacteria. As a result, the bacteria are unable to replicate and eventually die. Pretomanid has been shown to be effective against drug-resistant strains of tuberculosis.","oneSentence":"Pretomanid is a prodrug that is converted into its active form, which inhibits the enzyme dihydrofolate reductase (DHFR) in Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:53.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB)"}]},"trialDetails":[{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":"Pulmonary Tuberculosis","enrollment":109},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT04179500","phase":"PHASE2","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2021-09-16","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":26},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT05040126","phase":"PHASE3","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2021-10-07","conditions":"Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB, Non-responsive Multidrug-Resistant Pulmonary TB","enrollment":400},{"nctId":"NCT03086486","phase":"PHASE3","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":181},{"nctId":"NCT03202693","phase":"PHASE1","title":"A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2006-03","conditions":"Tuberculosis","enrollment":6},{"nctId":"NCT01498419","phase":"PHASE2","title":"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-03","conditions":"Pulmonary Tuberculosis","enrollment":207},{"nctId":"NCT01215851","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-10","conditions":"Pulmonary Tuberculosis","enrollment":85},{"nctId":"NCT01691534","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-10","conditions":"Pulmonary Tuberculosis","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pretomanid (Pa)","genericName":"Pretomanid (Pa)","companyName":"Wuhan Pulmonary Hospital","companyId":"wuhan-pulmonary-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pretomanid is a prodrug that is converted into its active form, which inhibits the enzyme dihydrofolate reductase (DHFR) in Mycobacterium tuberculosis. Used for Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}